OctoPlus signs controlled release technology deal with US firm
Will use PolyActive technology to develop compound
Dutch drug delivery firm OctoPlus has signed a feasibility agreement with a US-based pharmaceutical company relating to the use of OctoPlus' controlled release technology.
Under the contract, Leiden-based OctoPlus will develop a controlled release formulation of an undisclosed compound using its proprietary drug delivery technology PolyActive. If the evaluation is successful, the companies may decide to enter into a full process development, manufacturing and licensing agreement.
Further details and financial terms were not disclosed.
This agreement follows a separate pharmaceutical development and manufacturing contract signed by OctoPlus in July with The Medicines Company in the US.
In this deal, OctoPlus will carry out process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).
These two contracts are examples of the services offered by OctoPlus: drug delivery technologies for the development of controlled release versions of existing or new drugs, and formulation development and clinical material manufacturing services. The firm also has expertise in formulation and manufacturing.
